Copyright
©The Author(s) 2021.
World J Gastroenterol. Apr 28, 2021; 27(16): 1785-1804
Published online Apr 28, 2021. doi: 10.3748/wjg.v27.i16.1785
Published online Apr 28, 2021. doi: 10.3748/wjg.v27.i16.1785
Table 1 Correlation of expression of MRPL35 with various clinicopathological features in 68 gastric carcinoma patients
Pathological feature | n | Expression of MRPL35 | ||
High | Low | P value | ||
68 | 28 | 40 | ||
Gender | ||||
Male | 48 | 19 | 29 | 0.685 |
Female | 20 | 9 | 11 | |
Age (yr) | ||||
< 65 | 33 | 18 | 15 | 0.03a |
≥ 65 | 35 | 10 | 25 | |
p-TNM stage | ||||
I/II | 33 | 9 | 24 | 0.024a |
III/IV | 35 | 19 | 16 | |
Size of tumour | ||||
≤ 5 cm | 29 | 9 | 20 | 0.1 |
> 5 cm | 39 | 19 | 20 | |
Pathological T grade | ||||
T1/T2 | 11 | 3 | 8 | 0.313 |
T3/T4 | 57 | 25 | 32 | |
Lymph node metastasis (pN) | ||||
N0/N1 | 30 | 7 | 23 | 0.007b |
N2/N3 | 38 | 21 | 17 |
- Citation: Yuan L, Li JX, Yang Y, Chen Y, Ma TT, Liang S, Bu Y, Yu L, Nan Y. Depletion of MRPL35 inhibits gastric carcinoma cell proliferation by regulating downstream signaling proteins. World J Gastroenterol 2021; 27(16): 1785-1804
- URL: https://www.wjgnet.com/1007-9327/full/v27/i16/1785.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i16.1785